Feasibility Study of an Accommodating IOL Design

NCT ID: NCT07147192

Last Updated: 2025-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study is to assess safety and explore usability and effectiveness of the test product, AAL-FAIOL. This study will be conducted in Central America.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will enroll adult subjects who require cataract surgery in both eyes. One eye will receive the AAL-FAIOL and the other eye will receive the BAL-FAIOL. The two eye surgeries will be separated by 14-35 days. Subjects will attend follow up visits for approximately 1 year. If needed, the AAL lens may be adjusted after surgery with a laser to help give the participant better vision.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aphakia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Contralateral implantation
Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AAL-FAIOL

The clouded lens will be removed by phacoemulsification, after which the AAL-FAIOL will be implanted in one eye.

Group Type EXPERIMENTAL

AAL-FAIOL

Intervention Type DEVICE

Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject. Laser energy to specified locations can be used to allow a change in power for far distances.

Phacoemulsification

Intervention Type PROCEDURE

Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for intraocular lens (IOL) implantation.

BAL-FAIOL

The clouded lens will be removed by phacoemulsification, after which the BAL-FAIOL will be implanted in one eye.

Group Type EXPERIMENTAL

BAL-FAIOL

Intervention Type DEVICE

Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.

Phacoemulsification

Intervention Type PROCEDURE

Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for intraocular lens (IOL) implantation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AAL-FAIOL

Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject. Laser energy to specified locations can be used to allow a change in power for far distances.

Intervention Type DEVICE

BAL-FAIOL

Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.

Intervention Type DEVICE

Phacoemulsification

Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for intraocular lens (IOL) implantation.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to understand and sign an Informed Consent Form.
* Willing and able to attend all scheduled study visits required per protocol.
* Diagnosed with bilateral cataracts requiring removal by phacoemulsification.
* Preoperative corneal astigmatism equal to or less than 1.50 diopter (D) in both eyes.

Exclusion Criteria

* Women of childbearing potential who are pregnant, intend to become pregnant during the study, or are breastfeeding.
* Taking medications that could increase risk or may affect accommodation.
* Eye conditions as specified in the protocol, including glaucoma or ocular hypertension.
* Medical conditions that could increase operative risk as specified in the protocol.
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trial Lead, Surgical

Role: STUDY_DIRECTOR

Alcon Research, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Contact Alcon Call Center for Trial Locations

Fort Worth, Texas, United States

Site Status

Clinica 20/20

San José, , Costa Rica

Site Status

Instituto Espaillat Cabral

Santo Domingo, , Dominican Republic

Site Status

Centro Panamericano de Ojos / Clinica Lopez Beltran

San Salvador, , El Salvador

Site Status

Panama Eye Center

Panama City, , Panama

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Costa Rica Dominican Republic El Salvador Panama

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alcon Call Center

Role: CONTACT

Phone: 1-888-451-3937

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ILK345-E001

Identifier Type: -

Identifier Source: org_study_id